Lotronex (alosetron) blocks the action of a chemical referred to as monoamine neurotransmitterwithin the intestines. This slows the movement of stools (bowel movements) through the intestines.

Lotronex is employed to treat severe, chronic irritable viscus syndrome (IBS) in ladies United Nations agency have had diarrhoea because the main symptom for a minimum of six months. Lotronex ought to be used solely in ladies United Nations agency have tried different IBS treatments while notsuccess. This drugs has not been shown to be effective in men with IBS.

Lotronex is obtainable solely underneath a special program referred to as the Titan Prescribing Program. you want to be registered within the program and sign documents stating that you simplyperceive the risks and advantages of taking this medication.

Lotronex may additionally be used for functions ex-directory during this medication guide.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Lotronex
  • Applies to alosetron: oral tablet

    In addition to its needed effects, some unwanted effects may be caused by alosetron (the active ingredient contained in Lotronex). In the event that any of these side effects do occur, they may require medical attention.

    You should check with your doctor immediately if any of these side effects occur when taking alosetron:

    More common
    Constipation
    Rare
    Bloody diarrhea
    new or worsening stomach pain or discomfort
    rectal bleeding
    Incidence not known
    Abdominal or stomach pain, cramping, or burning
    black, tarry stools
    diarrhea
    fever
    heartburn
    indigestion
    nausea
    vomiting with or without blood or material that looks like coffee grounds
    If any of the following symptoms of overdose occur while taking alosetron, get emergency help immediately:

    Symptoms of overdose
    Clumsiness, unsteadiness, trembling, or other problems with muscle control or coordination
    convulsions (seizures)
    difficulty breathing
    shakiness and unsteady walk
    withdrawn or socially detached behavior
    Some of the side effects that can occur with alosetron may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

    Less common
    Bleeding after bowel movement
    full or bloated feeling
    pressure in the stomach
    swelling of abdominal or stomach area
    uncomfortable swelling around rectal area
    Incidence not known
    Headache
    skin rash
  • To lower the risk of constipation, LOTRONEX should be started at a dosage of 0.5 mg twice a day. Patients who become constipated at this dosage should stop taking LOTRONEX until the constipation resolves. They may be restarted at 0.5 mg once a day. If constipation recurs at the lower dose, LOTRONEX should be discontinued immediately. Patients well controlled on 0.5 mg once or twice a day may be maintained on this regimen. If after 4 weeks the dosage is well tolerated but does not adequately control IBS symptoms, then the dosage can be increased to up to 1 mg twice a day. LOTRONEX should be discontinued in patients who have not had adequate control of IBS symptoms after 4 weeks of treatment with 1 mg twice a day. LOTRONEX can be taken with or without food. LOTRONEX should be discontinued immediately in patients who develop constipation or signs of ischemic colitis. LOTRONEX should not be restarted in patients who develop ischemic colitis. Clinical trial and postmarketing experience suggest that debilitated patients or patients taking additional medications that decrease gastrointestinal motility may be at greater risk of serious complications of constipation. Therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients. Postmarketing experience suggests that elderly patients may be at greater risk for complications of constipation; therefore, appropriate caution and follow-up should be exercised if LOTRONEX is prescribed for these patients.